PDS Biotechnology Corp
PDSB0.890USD
+0.014+1.57%
收盤 12/19, 16:00（美東）報價延遲15分鐘
42.46M總市值
虧損本益比TTM
關於 PDS Biotechnology Corp 公司
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
PDS Biotechnology Corp簡介
公司代碼PDSB
公司名稱PDS Biotechnology Corp
上市日期Oct 01, 2015
CEOBedu-Addo (Frank)
員工數量24
證券類型Ordinary Share
年結日Oct 01
公司地址303A College Road East
城市PRINCETON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編08540
電話18002083343
網址https://www.pdsbiotech.com
公司代碼PDSB
上市日期Oct 01, 2015
CEOBedu-Addo (Frank)
PDS Biotechnology Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
Mr. Spencer Brown
Mr. Spencer Brown
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. Stephan Toutain
Mr. Stephan Toutain
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Kirk V. Shepard, M.D.
Dr. Kirk V. Shepard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月18日 週二
更新時間: 11月18日 週二
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
3.63%
Bedu-Addo (Frank)
1.32%
BlackRock Institutional Trust Company, N.A.
0.97%
Geode Capital Management, L.L.C.
0.92%
Sykes (Richard)
0.85%
其他
92.31%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
3.63%
Bedu-Addo (Frank)
1.32%
BlackRock Institutional Trust Company, N.A.
0.97%
Geode Capital Management, L.L.C.
0.92%
Sykes (Richard)
0.85%
其他
92.31%
股東類型
持股股東
佔比
Investment Advisor
6.46%
Individual Investor
2.69%
Investment Advisor/Hedge Fund
2.14%
Hedge Fund
1.29%
Research Firm
0.65%
Bank and Trust
0.22%
Venture Capital
0.04%
其他
86.51%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
178
7.65M
16.41%
-3.65M
2025Q2
188
9.63M
21.07%
+1.19M
2025Q1
201
9.77M
22.08%
+1.54M
2024Q4
205
5.67M
12.73%
-3.40M
2024Q3
205
5.76M
15.58%
-3.85M
2024Q2
208
6.94M
18.83%
-4.50M
2024Q1
195
8.96M
25.12%
-3.13M
2023Q4
194
9.68M
31.15%
-1.91M
2023Q3
192
9.20M
29.70%
-3.29M
2023Q2
183
9.26M
30.03%
-1.73M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
1.95M
4.18%
+441.12K
+29.21%
Jun 30, 2025
Bedu-Addo (Frank)
690.87K
1.48%
--
--
Apr 17, 2025
BlackRock Institutional Trust Company, N.A.
505.09K
1.08%
+24.12K
+5.01%
Jun 30, 2025
Geode Capital Management, L.L.C.
417.93K
0.9%
-19.95K
-4.56%
Jun 30, 2025
Sykes (Richard)
445.11K
0.95%
--
--
Apr 17, 2025
Citadel Advisors LLC
249.03K
0.53%
+249.03K
--
Jun 30, 2025
Inspirion Wealth Advisors, LLC
344.39K
0.74%
+265.86K
+338.54%
Sep 30, 2025
Squarepoint Capital LLP
97.77K
0.21%
+97.77K
--
Jun 30, 2025
Renaissance Technologies LLC
105.69K
0.23%
+105.69K
--
Jun 30, 2025
William Blair & Company, L.L.C. (Research)
250.00K
0.54%
-7.20K
-2.80%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
Global X Russell 2000 Covered Call ETF
0%
ProShares UltraPro Russell2000
0%
Invesco NASDAQ Future Gen 200 ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.01%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
Global X Russell 2000 Covered Call ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Invesco NASDAQ Future Gen 200 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
PDS Biotechnology Corp的前五大股東是誰？
PDS Biotechnology Corp的前五大股東如下：
The Vanguard Group, Inc.持有股份：1.95M佔總股份比例：4.18%。
Bedu-Addo (Frank)持有股份：690.87K佔總股份比例：1.48%。
BlackRock Institutional Trust Company, N.A.持有股份：505.09K佔總股份比例：1.08%。
Geode Capital Management, L.L.C.持有股份：417.93K佔總股份比例：0.90%。
Sykes (Richard)持有股份：445.11K佔總股份比例：0.95%。
The Vanguard Group, Inc.持有股份：1.95M佔總股份比例：4.18%。
Bedu-Addo (Frank)持有股份：690.87K佔總股份比例：1.48%。
BlackRock Institutional Trust Company, N.A.持有股份：505.09K佔總股份比例：1.08%。
Geode Capital Management, L.L.C.持有股份：417.93K佔總股份比例：0.90%。
Sykes (Richard)持有股份：445.11K佔總股份比例：0.95%。
PDS Biotechnology Corp的前三大股東類型是什麼？
PDS Biotechnology Corp 的前三大股東類型分別是：
The Vanguard Group, Inc.
Bedu-Addo (Frank)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Bedu-Addo (Frank)
BlackRock Institutional Trust Company, N.A.
有多少機構持有PDS Biotechnology Corp(PDSB)的股份？
截至2025Q3，共有178家機構持有PDS Biotechnology Corp的股份，合計持有的股份價值約為7.65M，占公司總股份的16.41% 。與2025Q2相比，機構持股有所增加，增幅為-4.66%。
哪個業務部門對PDS Biotechnology Corp的收入貢獻最大？
在--，--業務部門對PDS Biotechnology Corp的收入貢獻最大，創收--，占總收入的--% 。
